Dermato-Onco2024 | Redefining the need for SLN biopsies in high-risk melanoma diagnosis
Julian Kӧtt
• 5 Nov 2024
Julian Kӧtt, MD, University Medical Center Hamburg, Hamburg, Germany, comments on the likelihood of standardizing tissue-base profiling in clinical practice to assess sentinel lymph node (SLN) risk in patients with primary cutaneous melanoma. Prospective studies are necessary to investigate the diagnostic value of protein-based signatures in patients with primary cutaneous melanoma and subsequently, and the effectiveness of therapies for high-risk melanoma. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
